Health Technology · Pharmaceuticals: Major · NSE: SHUKRAPHAR · data 2026-10-09

Shukra Pharmaceuticals Ltd.

Health check: Strong (6.5/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹66.94

Market cap

₹2,943 cr

P/E

86.4

P/B

—

ROE

28.9%

ROCE

31.3%

Debt / equity

0.06

Dividend yield

0.01%

1-year return

59.2%

52-week high

₹75.4

52-week low

₹40.06

Operating margin

57.2%

Growth

Revenue (last 12 months)	₹75 cr
Net profit (last 12 months)	₹34 cr
Sales growth, 3 years (yearly)	-1.2%
Profit growth, 3 years (yearly)	71.0%

Similar companies

Ind-Swift Laboratories Ltd. (INDSWFTLAB) · Solara Active Pharma Sciences Ltd. (SOLARA) · Hikal Limited (HIKAL) · Alembic Limited (ALEMBICLTD) · Fredun Pharmaceuticals Ltd. (FREDUN)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open SHUKRAPHAR in NSE Scanner →